Second-generation antipsychotic with high-affinity D2 and 5-HT2A antagonism, 5-HT7 antagonism, 5-HT1A partial agonism, and negligible H1 / M1 / α1 activity — predicts a favourable metabolic and sedation profile relative to older atypicals. Oral bioavailability is ~2× with a ≥350 kcal meal; FDA labelling requires food co-administration.
Half-Life & Elimination Curve (PO: 18h)
Plasma (PO)t½ Decay (18h)Effect Site (ke0)
0×t½0h100%(26.5 µg/L)
1×t½18h50%(13.2 µg/L)
2×t½36h25%(6.61 µg/L)
3×t½54h12.5%(3.31 µg/L)
4×t½3d6.3%(1.65 µg/L)
5×t½3.8d3.1%(0.827 µg/L)
Elimination t½18h (PO)
Rate Constant (ke)0.0385 h⁻¹
Time to Peak (Tmax)2h
Est. Peak (Cmax)26.5 µg/L
Clearance (CL)16.2 L/h
97% Washout (5×t½)3.8d
Dosing Guidelines
Oral (PO): Typical 80 mg (Range: 40–160 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 15% · Volume of Distribution (Vd): 420 L · Absorption (ka): 2.02 h⁻¹ (t½ka ≈ 21m) [PMID 27722855]